Study to Evaluate the Pharmacokinetics, Safety, Tolerability of 100 mg Multiple Doses of GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects

Trial Profile

Study to Evaluate the Pharmacokinetics, Safety, Tolerability of 100 mg Multiple Doses of GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Sep 2016

At a glance

  • Drugs Filgotinib (Primary)
  • Indications Crohn's disease; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Galapagos NV
  • Most Recent Events

    • 08 Nov 2015 Results will be presented at the American College of Rheumatology (ACR) Annual Meeting 2015, according to a Galapagos NV media release.
    • 21 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top